Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.31 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5970723 | 1.00 | TP53 (0.50) | TP53TSHRSLC7A5ENPEPRNPEP | |
| SCHEMBL28265924 | 0.81 | TP53 (0.50) | TP53TSHRSLC7A5RNPEP | |
| SCHEMBL1124153 | 0.80 | TP53 (0.56) | TP53TSHRSLC7A5RNPEP | |
| SCHEMBL3700252 | 0.75 | TSHR (0.53) | TP53TSHRSLC7A5 | |
| SCHEMBL15841482 | 0.75 | TSHR (0.53) | TP53TSHRSLC7A5 | |
| SCHEMBL28314569 | 0.73 | TP53 (0.47) | TP53TSHRSLC7A5RNPEP | |
| SCHEMBL10481616 | 0.73 | TP53 (0.47) | TP53TSHRSLC7A5 | |
| SCHEMBL11059297 | 0.73 | TSHR (0.50) | TP53TSHRSLC7A5 | |
| SCHEMBL12904430 | 0.73 | TSHR (0.50) | TP53TSHRSLC7A5 | |
| SCHEMBL265598 | 0.73 | TSHR (0.50) | TP53TSHRSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293946-A1 | Process for Preparing Zolpidem Hemitartrate and Tartrate Polymorphs | MALLINCKRODT INC. | 2008-11-27 | — | — | US | disclosed |
| EP-1948655-A1 | PROCESS FOR PREPARING ZOLPIDEM HEMITARTRATE AND TARTRATE POLYMORPHS | MALLINCKRODT, INC. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007040995-A1 | PROCESS FOR PREPARING ZOLPIDEM HEMITARTRATE AND TARTRATE POLYMORPHS | MALLINCKRODT INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| EP-1163241-B1 | ZOLPIDEM SALTS | SYNTHON BV (NL) | 2005-06-15 | — | — | EP | disclosed |
| US-6242460-B1 | DOES NOT EXHIBIT A MELTING ENDOTHERM THAT CORRESPONDS TO ZOLPIDEM FREE BASE. | SYNTHON BV (NL) | 2001-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293946-A1 | Process for Preparing Zolpidem Hemitartrate and Tartrate Polymorphs | CYP4A11, ADH1A, CYP26A1 | TP53 2252/4885TSHR 228/4885SLC7A5 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.